Fangyuan Capital

The group deploys a co-chief investment officer structure. Linlin Ma and Zhibin Zhang serve jointly as Co-CIOs at the parent level, with both having direct trading and research backgrounds spanning Deutsche Bank and Chinese brokerages. Their credit fund and private-equity units each carry separate executive teams, with Sophia Tan and Matthew Chan as co-CEOs of the Fangyuan Fund and Christine Zheng as chairman of Fangyuan Capital.

Fangyuan's fixed-income team leans on decades of sell-side and buy-side relationships across Asian credit desks — Chad Liu's background in dollar high-yield and Thomas Deng's former Goldman Sachs strategy role feed primary-issue access. On the private-equity side, Fangyuan Capital structures biomedical fund-of-funds and single-project vehicles, implying manager-selection and co-investment networks in life sciences rather than purely direct origination.

Fangyuan is structured as an asset manager, not a single family office. It holds Hong Kong SFC Type 4 and Type 9 licenses and a Singapore CMS license, and operates a brand that accepts external capital. It does maintain a family-office service unit that draws on the Wing Lung Bank founding Wu family's experience, but that unit provides wealth-planning services to third parties rather than managing a sole family's assets.

It does both. Its credit strategy makes direct secondary-market investments in bonds, convertibles, and derivatives, while the private-equity arm runs two biomedical fund-of-funds alongside single-project vehicles — meaning it both commits to external managers and conducts direct healthcare and life-sciences investments.

Fangyuan Capital focuses on life sciences and healthcare, operating fund-of-funds that likely span venture to growth equity given the typical biomedical fund structure. Single-project funds suggest a spillover into direct growth and later-stage pre-IPO opportunities, though the firm does not publicly disclose stage minimums or check sizes.

No negative screening policy is published. Observed allocations — Asian credit, biomedical fund-of-funds, and life-science single-project vehicles — imply it currently avoids sectors such as consumer tech, industrial manufacturing, and hard infrastructure, though this reflects investment choices rather than a stated exclusion.

The firm has not disclosed any philanthropic foundation or donor-advised fund. The group description mentions the Wing Lung Bank Wu family's fourth-generation estate-planning experience, but this is embedded in a commercial trust and family-office service line, not a charitable structure.